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ABSTRACT 
Objective: Hypertension (HTN) is both a cause and an effect of chronic kidney disease (CKD). To adequately control blood pressure (BP) in CKD, 
choosing antihypertensive strategies with the highest nephro-protective effect is crucial for preventing or reversing end-stage renal disease (ESRD) 
progression and reducing cardiovascular disease (CVD) risk. The present study was therefore designed to evaluate the impact of clinical use of 
antihypertensive drug therapy in patients with CKD and ESRD. 
Methods: It is a prospective observational cohort study. The patients were divided into two cohorts i.e.; non-dialysis dependent (NDD) and dialysis-
dependent (DD) CKD. This study was conducted for six months in the Nephrology department, Osmania General Hospital, Hyderabad, India. The 
data collected and entered into Microsoft Excel (2007) and mean, SD and range were calculated using SPSS version 25. 
Results: Antihypertensive drugs were prescribed alone or in combination based on the co-morbidities associated with CKD and HTN. Loop diuretics 
(Furosemide and Torsemide) and calcium channel blocker (Amlodipine, Nifedipine and Cilnidipine) were most commonly prescribed 
antihypertensive drugs. Triple therapy (44.11%) was prescribed mostly in both the cohorts (NDD = 16.66%+DD = 27.45%) of which calcium 
channel blockers+loop diuretic+sympatholytic accounts for 19.16% (NDD = 5.88%+DD = 13.73%).  
Conclusion: The practice of prescribing antihypertensive drugs for the management of HTN and to achieve BP targets in CKD and ESRD remains 
uncertain. The development of new and revised guidelines is needed to reduce inappropriate variations in practice and promote better delivery of 
evidence-based treatment. 
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Chronic kidney disease (CKD) with its high prevalence, morbidity and 
mortality, is an important public health challenge [1]. According to the 
2012 KDIGO clinical practice guidelines, CKD is defined as 
‘abnormalities of kidney structure or function, present for>3 mo, with 
implications for health.’ Criteria for CKD (Either of the following 
presents for>3 mo): Markers of kidney damage (one or more): 
Albuminuria (ACR ≥ 30 mg/g), Urine sediment abnormalities, 
Electrolyte and other abnormalities due to tubular disorders, 
Pathological abnormalities detected by histology, Structural 
abnormalities detected by imaging, History of kidney transplantation; 
Decreased glomerular filtration rate (GFR)<60 ml/min/1.73m2
CKD and ESRD represent worldwide public health problems with an 
epidemic extent
 [2]. 
 [3, 4]. From 1990-2013 the age-adjusted death rates 
attributable to CKD increased by 36.9% in 188 countries surveyed 
and CKD is now the 19th leading cause of life years lost [5]. 
Hypertension (HTN) is a major risk factor for cardiovascular and 
renal disease. Conversely, CKD is the most common form of 
secondary hypertension [9]. HTN is present in 50% to 80% of 
patients with CKD [10] defined as the persistent elevation of systolic 
blood pressure (SBP) ≥140 m mHg and diastolic blood pressure 
(DBP) ≥90 mmHg [11]. It is a strong independent, modifiable risk 
factor for CKD and contributes to the disease itself or, most 
commonly, to its progression [12]. It may develop early during the 
CKD and may contribute to adverse outcomes such as worsening of 
renal function or progression of kidney disease towards ESRD, 
development of cardiovascular diseases (CVD) such as heart attack 
and stroke and high cardiovascular morbidity and mortality [13-15]. 
In India, 
the incidence of CKD is rising and as per estimates from 2006, the 
age-adjusted incidence rate of ESRD is 229 per million population 
[6]. In 2015, CKD affected about 323 million people globally and 
resulted in 1.2 million deaths, up from 4,09,000 in 1990 [7]. The 
causes that contribute to the greatest number of deaths are 
hypertension at 5,50,000 followed by diabetes at 4,18,000 and 
glomerulonephritis at 2,38,000 [8]. 
Thus, HTN and CKD are inextricably linked with both cause and 
effect relationships [16]. It is well established that albuminuria and 
reduced GFR, in both diabetic and non-diabetic hypertensive CKD 
patients, are major cardiovascular risk factors and many older 
patients develop or die from cardiovascular disease rather than 
progress to ESRD [17, 18]. In particular, this may be due to 
inadequate control of HTN in patients with CKD [19]. 
There is some evidence that BP should be reduced below 130/85 mm 
Hg in patients with diabetic and non-diabetic nephropathies 
and<125/75 mm Hg in patients with non-diabetic nephropathies and 
proteinuria>1 g/day and the available data suggests that tight BP 
control (BP<140/80 mm Hg) can reduce the risk of cardiovascular 
complications in hypertensive patients with type 2 diabetes mellitus 
[20]. The JNC VIII guidelines for HTN in patients>18 y old with CKD 
recommend a goal BP of<140/90 mmHg regardless of CKD stage or 
proteinuria. Other recommendations, including those by the KDIGO 
study in 2012, recommend a similar goal blood pressure of<140/90 
mmHg in most CKD patients, but stricter control (<130/80 mmHg) in 
those with>30 mg/day proteinuria [21]. 
Aggressive treatment of HTN has been a key component [22] 
relevant at all stages of the disease, irrespective of the underlying 
cause [23, 25] as it is associated with improved cardiovascular 
outcomes in both CKD and ESRD [24]. Antihypertensive drugs are 
therefore recommended in patients with CKD with or without HTN 
as these agents provide cardio-protective and reno-protective 
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benefits [25]. Antihypertensive drugs are therefore used in CKD to 
(1) Reduce BP; (2) Reduce the risk of CVD, and (3) slow the 
progression of kidney disease [26]. Recent guidelines for the 
treatment of HTN in CKD suggest the use of a variety of 
antihypertensive drugs to achieve the desired BP levels. Usually, a 
combination of two or more antihypertensive drugs is required to 
control HTN. Antihypertensive treatment is individualized to each 
patient depending on the age, severity of albuminuria, tolerance, 
compliance and specific clinical features [17, 21, 27]. 
In the present study, current evidence supporting treatment of HTN 
with antihypertensive drugs in CKD was reviewed and the study was 
therefore designed and performed to evaluate the impact of 
antihypertensive drug therapy in patients with CKD (Non-dialysis 
dependent) and ESRD (Dialysis dependent) in association with the 
patients’ clinical or disease outcomes. 
MATERIALS AND METHODS 
The present study carried out to determine the impact of 
antihypertensive drug therapy in CKD patients with HTN. Ethical 
clearance was obtained from the Institutional Ethics Committee (No. 
MCP/IEC/PD/PR/30) before the commencement of the project. The 
duration of the study was six (6) months. The study was carried out in 
the Inpatient Department of Nephrology, Osmania General Hospital, a 
tertiary care teaching hospital, Hyderabad, Telangana, India.  
Study design 
This is a hospital-based prospective observational cohort study. The 
patients were divided into two cohorts i.e.; non-dialysis dependent 
(NDD) and Dialysis dependent (DD) CKD based on the history of 
albuminuria, estimated glomerular filtration rate (eGFR) and the 
requirement for dialysis.  
The study was conducted on 120 patients with presumed and/or 
confirmed CKD with HTN, but 18 patients were excluded based on 
the inclusion and exclusion criteria. 06 patients were lost to follow 
up, 12 patients were excluded after clinical judgment (AKI, 
Autoimmune disease, Current Infection, and Lactating woman; 
age<18). The remaining 102 patients were evaluated during the 
study. 
Study population 
After written informed consent was obtained following national 
guidelines, the subjects for the study were selected based on the 
following criteria that include: Patients of either sex, Age group 
≥18years, Patients diagnosed as CKD Stages III-V and ESRD patients 
on hemodialysis. Terminally ill patients co-infected with HIV or 
hepatitis or with any infective conditions or with any autoimmune 
diseases, Patients of age group<18yrs, Patients with acute kidney 
injury (AKI), Surgical conditions like kidney stones, tumors, trauma 
and CKD patients with renal transplant, Pregnant and lactating 
women, individuals who are not willing to give consent were 
excluded. 
Inclusion and exclusion criteria 
Data collection 
Proforma was designed covering all the necessary parameters. Data 
was collected from medical record sheet, patients and their 
attendants. The study related Physical examination, Clinical and 
Biochemical findings including BP (SBP and DBP), eGFR, serum 
electrolytes, serum creatinine, serum urea, albuminuria along with 
radiological findings including USG, X-ray and CT scan of the 
abdomen were documented and assessed at the time of admission 
and discharge as per the available literature. The data was used to 
determine the impact of antihypertensive drugs on the study 
cohorts. 
Data analysis 
The data was recorded, tabulated using Microsoft Excel 2007 
version and descriptive analysis (mean, SD and range) 
performed using SPSS version 25. 
  
 
Fig. 1: Flow Chart of the Study cohort, AKI: Acute Kidney Injury; HIV: Human Immune Virus; NDD: Non-Dialysis Dependent; DD: Dialysis 
Dependent; HD: Haemodialysis; CKD-EPI: (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation (2009) 
 
RESULTS 
A total of 102 patients were observed to study the cardio-protective 
and reno-protective effect of antihypertensive drugs during their 
stay at the hospital. These patients were divided into two cohorts 
viz. non-dialysis dependent (NDD) CKD (Cohort 1) and Dialysis 
dependent (DD) CKD (Cohort 2) depending upon the extent of 
kidney damage and dialysis required. 
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Table 1: Patients’ characteristics in two cohort groups 
Characteristics NDD-CKD (Cohort 1) N = 33 No. of Patients (%) DD-CKD (Cohort 2) N = 69 No. of Patients (%) 
Age (years) Male 
(n = 22) 
Female 
(n = 11) 
Male 
(n = 37) 
Female 
(n = 32) 
18-27 2 (1.96%) 1 (0.98%) 3 (2.94%) 2 (1.96%) 
28-37 5 (4.90%) 1 (0.98%) 6 (5.88%) 3 (2.94%) 
38-47 3 (2.94%) 4 (3.92%) 11 (10.78%) 5 (4.90%) 
48-57 1 (0.98%) 1 (0.98%) 8 (7.84%) 6 (5.88%) 
58-67 10 (9.80%) 4 (3.92%) 7 (6.86%) 11 (10.78%) 











Ex-Smoker 3 (2.94%) 2 (1.96%) 2 (1.96%) 0 (0.00%) 
Non smoker 16 (15.69%) 9 (8.82%) 29 (28.43%) 31 (30.39%) 
Co-morbidities 











0 (0.00%) 1 (0.98%) 4 (3.92%) 0 (0.00%) 
Diabetes 10 (9.80%) 13 (12.75%) 8 (7.84%) 12 (11.76%) 
CVD 11 (10.78%) 10 (9.80%) 16 (15.69%) 28 (27.45%) 
Stroke 0 (0.00%) 1 (0.98%) 0 (0.00%) 2 (1.96%) 









































HTN–Hypertension, CVD–Cardiovascular Disease, NDD–Non-Dialysis Dependent, DD–Dialysis Dependent, CKD-Chronic Kidney Disease, eGFR–
Estimated Glomerular Filtration Rate. 
 
The mean age of CKD in NDD patients was 49.30±15.20 (Range=68-20) 
and in DD patients were 50.25±14.69 (Range=80-20). Majority of the 
patients (57.84%) were male in both the study cohorts (NDD=21.57% 
and DD=36.27%). In study cohorts, n=97(95.10%) were hypertensive 
(HTN as a CAUSE) and were receiving antihypertensive medications and 
n=5(04.90%) were newly diagnosed with HTN (HTN as an EFFECT). 
Most of the patients in both the cohorts were at G5/A3 stage (61.76%) 
followed by G4/A3 (15.69%). 
 
Table 2: Percentage of antihypertensive drugs prescribed 







Angiotensin II Receptor Blockers (ARB) Telmisartan 2.94% 
Adrenergic  
Antagonists 
Alpha Blockers (AB) Prazosin 2.94% 
Beta Blockers (BB) Atenolol 8.82% 
Metoprolol 22.55% 
Alpha+Beta Blockers (ABB) Labetalol 2.94% 
Adrenergic Agonists Centrally Acting  Alpha2 Clonidine Agonist/Sympatholytic (CAAA/SYM) 27.45% 
Calcium Channel  
Blockers (CCB) 
Dihydropyridines (DHP) Amlodipine 81.37% 
Nifedipine 7.84% 
Cilnidipine 1.96% 
Diuretics (D) Loop Furosemide 84.30% 
Torsemide 4.90% 
Thiazide Like Metolazone 1.96% 
Potassium Sparing Spironolactone 2.94% 
 
In both, the study cohorts, the most commonly prescribed class of 
antihypertensive drugs was diuretics (D) (93.40%) followed by 
calcium channel blockers (CCBs) (93.17%). Furosemide (84.30%) 
and Amlodipine (81.37%) were the most commonly prescribed 
antihypertensive drugs followed by Clonidine (27.45%) in 
combination with other antihypertensive drugs in the study cohorts. 
 
Antihypertensive drugs were prescribed alone or in combination 
based on the co-morbidities associated with CKD and HTN. All the 
patients (N=102) in the study were diagnosed with CKD and HTN 
with the evidence of albuminuria. Triple therapy (44.11%) was 
prescribed mostly in both the Cohorts (NDD = 16.66%+DD = 
27.45%).
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Table 3: Percentage of antihypertensive drugs prescribed for the treatment of hypertension with associated co-morbidities in cohort 1 
and cohort 2 
Hypertension and  associated Co-morbidities Antihypertensive therapy prescribed Therapy received 
by NDD (%) 
Therapy received by 
DD (%) 
CKD+HTN+Albuminuria (X = 102) CCB (DHP) 0.98% 4.90% 
X+Fluid Overload CCB (DHP)+D (loop) 1.96% 12.75% 
CCB+D (loop)+SYM 0.00% 1.96% 
AB+D (loop)+SYM 0.00% 0.98% 
CCB (DHP)+D (loop)+ABB 0.00% 2.94% 
CCB (DHP)+D (loop)+BB+SYM 0.00% 3.92% 
X+DM CCB (DHP)+BB 0.98% 0.98% 
X+CAD/PVD CCB (DHP)+BB 0.98% 0.00% 
CCB (DHP)+RAS 0.98% 0.00% 
X+Fluid overload+DM BB+D (loop) 0.98% 0.00% 
CCB (DHP)+D (loop)+RAS 4.90% 0.98% 
RAS+D (loop)+BB 0.98% 1.96% 
CCB (DHP)+D (loop)+BB± 
D (Potassium Sparing) 
0.98% 11.76% 
X+Fluid overload±LVD/lVH CCB (DHP)+D (loop)+SYM 5.88% 13.73% 
X+Fluid overload+CCF CCB (DHP)+D (loop)+RAS+SYM 0.98% 0.00% 
BB+D (loop)+RAS+SYM 0.00% 0.98% 
X+DM+CCF CCB (DHP)+D (loop)+RAS 0.98% 0.00% 
3Ds (Loop, Potassium Sparing,  
Thiazide Like)+RAS+CCB 
0.00% 0.98% 
X+DM+CAD/PVD RAS+BB 1.96% 0.00% 
X+CCF/HF+DM+ 
CAD/PVD 
D (loop)+SYM 0.00% 0.98% 
CCB (DHP)+D (loop)+RAS+BB 2.94% 3.92% 
X+DM+LVD/lVH+CAD D (loop)+BB 0.00% 0.98% 
X+Fluid overload+DM+CAD/PVD D (loop)+BB 0.98% 0.00% 
CCB (DHP)+D (loop)+RAS 0.98% 2.94% 
X+Fluid overload+DM+Stroke RAS+CCB (DHP)+D (loop)+BB 0.98% 0.00% 
X+DM+LVD/lVH+CAD+Angina RAS+D (loop)+BB 1.96% 0.00% 
X+Fluid overload+DM+CAD/PVD+Stroke CCB (DHP)+D (loop) 0.98% 0.00% 
HTN = Hypertension, X = Hypertension+Albuminuria, DM = Diabetes Mellitus, LVD = Left Ventricular Dysfunction, LVH = Left Ventricular 
Hypertrophy, CAD = Coronary Artery Disease, PVD = Peripheral Vascular Disease, CCF = Congestive Cardiac Failure, HF = Heart Failure; AB = Alpha 
Blocker, ABB = Alpha+Beta Blocker, BB = Beta Blocker, CCB = Calcium Channel Blocker, DHP = Dihydropyridine, D = Diuretic, RAS = Renin 
Angiotensin System.   
 
Table 4: Indication for antihypertensive drug therapy prescribed to the study cohorts 
Antihypertensive drug Indication 
AB (Prazosin), ABB (Labetalol), D (Metolazone) Resistant Hypertension in DD patients 
ACEI (Enalapril), ARB (Telmisartan) HTN, DM, Proteinuria and Decreased eGFR, CCF, CAD/PVD, CVA, 
BB (Atenolol, Metoprolol)  HTN, DM to prevent CV complications, Angina, CCF,  
CCBs (Amlodipine, Nifedipine, Cilnidipine) HTN, Angina, CVA 
D (Furosemide and Torsemide) HTN, Fluid Overload, CCF, 
SYM (Clonidine) HTN, Pulmonary oedema and LVH/lVD 
Potassium Sparing Diuretic (Spironolactone) HTN, Drug-Induced Hypokalaemia 
 
Table 5: Assessment of blood pressure during admission and discharge in cohort 1 and cohort 2 receiving antihypertensive therapy 
BP (mmHg) (SYSTOLIC/DIASTOLIC) During admission No. of patients (Mean BP) During discharge No. of patients (Mean BP) 
NDD DD NDD DD 
Normal (≤ 120/80) 1 (110)/ 0 (0) 0 (0)/1 (70) 2 (110)/3 (70) 3 (110)/1 (60) 
Pre-Hypertension (120-139/80-89) 10 (130)/7 (80) 10 (130)/8 (80) 19 (127.4)/19 (80) 46 (127.8)/35 (80) 
Stage-1 Hypertension (140-159/90-99) 9 (145.5)/14 (90) 35 (147.1)/ 37 (90) 9 (144.4)/10 (90) 20 (141.5)/33 (90) 
Stage-2 Hypertension (≥ 160/100) 13 (180)/12 (106.6) 24 (176.7)/23 (104.5) 3 (160)/1 (100) 0 (0)/0 (0) 
n = No. of Patients. 
 
In study cohorts, BP was calculated and assessed during hospital 
admission and discharge based on the JNC VIII 2014 guidelines for 
the staging of HTN. Cohort 1 and 2 at the Stage-2 HTN and Cohort 2 
at the Stage-1 HTN (during hospital admission) have found to be 
effectively responded to the antihypertensive therapy prescribed.  
DISCUSSION 
There is a strong association between CKD and an elevated BP 
whereby each can cause or aggravate the other. A higher BP is 
generally associated with a higher CVD risk, making BP lowering an 
attractive goal to reduce CV morbidity and mortality. Thus, BP 
control is fundamental to the care of patients with CKD and is 
relevant at all stages of CKD (NDD or DD) regardless of the 
underlying cause [23].  
The predominance of the male in the study cohorts is similar to earlier 
studies [6, 17]. The prevalence of hypertension gradually increases as 
renal function deteriorates, and a high BP condition is almost universal 
in patients who progress to ESRD [28]. In the present study, the 
majority of the population were receiving haemodialysis apart from 
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antihypertensive therapy. These patients were grouped under 
dialysis-dependent (DD) CKD Cohort. 67.64% of patients were DD and 
32.36% were non-dialysis dependent (NDD) CKD patients.  
Multimorbidity is associated with CKD and HTN, of which 67.25% 
accounts for CVDs followed by DM (42.15%). Co-morbidities are 
important because they may impact on treatment burden, 
medications management, quality of life, and survival [29]. 
Therefore, antihypertensive drugs were prescribed to the study 
cohorts based on the co-morbidities associated.  
Patients with CKD are more likely to die, largely from CVD than 
require dialysis. Once they develop ESRD, dialysis patients have 
eight times the mortality rate of their age-matched counterparts in 
the general population, with cardiovascular causes accounting for 
more than 50% of deaths. It is, therefore, critically important to 
control modifiable risk factors (e. g., hypertension) in this high-risk 
group [9].  
The five classes of antihypertensive drugs prescribed to the cohorts were 
RAS antagonists, CCBs, BBs, Diuretics, and Sympatholytic. Loop diuretics 
(Furosemide and Torsemide) and calcium channel blocker (Amlodipine, 
Nifedipine and Cilnidipine) were the most commonly prescribed 
antihypertensive drugs. Furosemide accounts for 84.30% followed by 
Amlodipine 81.37%. The study shows the limited prescription of first-
line therapy (RAS) (29.41%), which has been shown to delay the 
progression of chronic kidney disease (CKD) [27, 30]. In the study 
cohorts, BB (31.37%) (Metoprolol and Atenolol) were commonly 
prescribed in DM and DD patients than NDD patients [31].  
The combination therapy most commonly prescribed in both the 
study cohorts was the triple therapy (44.11%) of which, CCB+loop 
diuretic+SYM regimen accounts for 19.16% (NDD = 5.88%+DD = 
13.73%). In DD patients, the second most commonly prescribed 
combination therapy was dual therapy regimen, CCB+loop diuretic 
accounting for 12.75%, whereas the four-drug regimen as second 
and third most prescribed in NDD and DD respectively. The 
Antihypertensive drugs were individualized and prescribed based 
on the associated risk factors and co-morbidities in the study 
cohorts (table 6) [9, 26]. Monotherapy (Amlodipine alone) was 
found to be ineffective, unlike RAS antagonists for the treatment of 
HTN in CKD with proteinuria. It is found to agree with the earlier 
reports [32]. 
Most of the NDD and DD patients (93.04%) at Stage 2 and DD 
patients at Stage 1 HTN were achieved significant decrease in BP 
with Triple, Four-drug and Dual therapy in order. From NDD and DD 
cohorts respectively, (n= 21/21) 20.58%/20.58% and (n= 49/36) 
48.03%/35.29% reached their (Systolic/Diastolic) BP goal 
of<130/80 mmHg; (n= 9/10) 8.82%/9.80% and (n= 20/33) 
19.61%/32.35% reached their (Systolic/Diastolic) BP goal 
of<140/90 mmHg.  
Findings 
In the present study, the impact of five different classes of 
antihypertensive drugs was evaluated. The outcomes of dual, triple 
and polytherapy were found to be effective in lowering BP, slowing 
down the progression of CKD and reducing the incidence of CV 
events, unlike monotherapy. Calcium channel blockers (CCB) in 
combination with the other drugs have shown the best 
cardioprotective and renoprotective outcomes in the study cohorts. 
Use of beta-blockers (BB) or calcium channel blockers (CCB) and 
diuretics (D)±Sympatholytic steadily increased, whereas use of 
renin-angiotensin system (RAS) Antagonist decreased with 
advancing CKD. Angiotensin-converting enzyme (ACE) Inhibitor was 
replaced by angiotensin II receptor blocker (ARB) in elderly patients 
(>60 y) as the former is primarily renally eliminated, thus 
potentially leading to accumulation in renal impairment than ARB, 
eliminated hepatically. Labetalol other than Atenolol and Metoprolol 
was additionally being used as a dialyzable agent in dialysis-
dependent CKD patients. Alpha-blockers like Prazosin and 
Sympatholytic like Clonidine and Diuretics caused postural 
hypotension in elderly patients; thus these drugs were used 
cautiously. Initiation of antihypertensive drug therapy other than 
the first-line therapy (RAS) in young patients resulted in the 
subsequent progression of CKD to ESRD and CV complications.  
The study is limited by its sample size, unicentric nature, a short 
period of six months and few classes of drugs prescribed. Further 
follow-up of patients is needed to increase the understanding of 
long-term effects and outcomes.  
CONCLUSION 
In conclusion, the practice of prescribing antihypertensive drugs for 
the management of hypertension and to achieve blood pressure 
targets in chronic kidney disease (CKD) and end-stage renal disease 
(ESRD) remains uncertain. Although, the prescription of 
antihypertensive drugs has been based on the standard treatment 
guidelines (NKF KDOQI 2004 and KDIGO 2012), the development of 
new and revised guidelines suggesting novel and effective therapies 
is needed to reduce inappropriate variations in practice and 
promote better delivery of evidence-based treatment. 
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